This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (52)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Steven Steinberg, MD; William Flynn, MD; Kathy Kelley, MD; Lon Bitzer, MD; Pramod Sharma; Cynthia Gutierrez; James Baxter, PharmD; David Lalka, PhD; Amy Sands, MD; Judy Van Liew, PhD; James Hassett, MD; Ray Price, PhD; Thomas Beam, MD; Lewis Flint, MD

Arch Surg. 1989;124(12):1390-1395.

Abstract
• Criteria that allow definition of the multiple organ failure syndrome include pulmonary, hepatic, renal, and gut barrier dysfunction along with characteristic histopathologic changes. It has been difficult to study multiple organ failure due to lack of a satisfactory experimental model that would reproduce the pathophysiologic and histopathologic characteristics, would be stable enough to allow study over several days, and would be free of exogenous primary bacterial infection. We have studied pathophysiologic and histopathologic alterations in a potential model of multiple organ failure. Wistar rats received one of the following solutions by intraperitoneal injection: 4 mL of saline, 4 mL of mineral oil, or 1 mg per gram of body weight of zymosan A in 4 mL mL of mineral oil. Animals that received zymosan developed hypoxia, decreased creatinine clearance, and changes in hepatic microsomal cytochrome P450 content and aniline hydroxylase activity. Bacterial translocation occurred in the zymosan group. The lungs, liver, and kidneys of the animals that received zymosan exhibited histopathologic changes. We conclude that this model fulfills our criteria for a model of multiple organ failure.

(Arch Surg. 1989;124:1390-1395)

Author Affiliations
From the Departments of Surgery (Drs Steinberg, Flynn, Kelley, Bitzer, Hassett, Price, and Flint, Mr Sharma, and Ms Gutierrez), Pharmaceutics (Drs Baxter and Lalka), Pathology (Dr Sands), and Medicine (Drs Van Liew and Beam), State University of New York at Buffalo and the Buffalo Veterans Administration Medical Center.

Footnotes
Accepted for publication August 4, 1989.

Read before the Ninth Annual Meeting of the Surgical Infection Society, Denver, Colo, April 13, 1989.

Reprint requests to Surgical Service, 3495 Bailey Ave, Buffalo, NY 14215 (Dr Steinberg).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adenoviral Delivery of Human and Viral IL-10 in Murine Sepsis
Minter et al.
J. Immunol. 2001;167:1053-1059.
ABSTRACT | FULL TEXT  

Chronic Type IV Phosphodiesterase Inhibition Protects Glomerular Filtration Rate and Renal and Mesenteric Blood Flow in a Zymosan-Induced Model of Multiple Organ Dysfunction Syndrome Treated with Norepinephrine
Thomas et al.
J. Pharmacol. Exp. Ther. 2001;296:168-174.
ABSTRACT | FULL TEXT  

Interleukin-13 Effectively Down-regulates the Monocyte Inflammatory Potential During Traumatic Stress
Kim et al.
Arch Surg 1995;130:1330-1336.
ABSTRACT  

Does Selective Decontamination of the Gastrointestinal Tract Prevent Multiple Organ Failure? An Experimental Study
Goris et al.
Arch Surg 1991;126:561-565.
ABSTRACT